LT3317300T - Bispecifiniai antikūnai, skirti panaudoti vėžio imunoterapijai - Google Patents

Bispecifiniai antikūnai, skirti panaudoti vėžio imunoterapijai

Info

Publication number
LT3317300T
LT3317300T LTEP16744669.9T LT16744669T LT3317300T LT 3317300 T LT3317300 T LT 3317300T LT 16744669 T LT16744669 T LT 16744669T LT 3317300 T LT3317300 T LT 3317300T
Authority
LT
Lithuania
Prior art keywords
bispecific antibodies
cancer immunotherapy
immunotherapy
cancer
bispecific
Prior art date
Application number
LTEP16744669.9T
Other languages
English (en)
Inventor
Mariangela Figini
Alessandro SATTA
Alessandro Massimo Gianni
Massimo DI NICOLA
Original Assignee
Fondazione Irccs Istituto Nazionale Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondazione Irccs Istituto Nazionale Dei Tumori filed Critical Fondazione Irccs Istituto Nazionale Dei Tumori
Publication of LT3317300T publication Critical patent/LT3317300T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP16744669.9T 2015-07-01 2016-07-01 Bispecifiniai antikūnai, skirti panaudoti vėžio imunoterapijai LT3317300T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15174741.7A EP3112381A1 (en) 2015-07-01 2015-07-01 Bispecific antibodies for use in cancer immunotherapy
PCT/EP2016/065577 WO2017001681A1 (en) 2015-07-01 2016-07-01 Bispecific antibodies for use in cancer immunotherapy

Publications (1)

Publication Number Publication Date
LT3317300T true LT3317300T (lt) 2021-05-10

Family

ID=53498900

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16744669.9T LT3317300T (lt) 2015-07-01 2016-07-01 Bispecifiniai antikūnai, skirti panaudoti vėžio imunoterapijai

Country Status (18)

Country Link
US (1) US10813995B2 (lt)
EP (2) EP3112381A1 (lt)
JP (1) JP6876006B2 (lt)
KR (1) KR20180053639A (lt)
CN (1) CN108602886B (lt)
AU (1) AU2016285118B2 (lt)
CA (1) CA2990517C (lt)
CY (1) CY1123839T1 (lt)
DK (1) DK3317300T3 (lt)
ES (1) ES2848391T3 (lt)
HR (1) HRP20210152T1 (lt)
HU (1) HUE053128T2 (lt)
LT (1) LT3317300T (lt)
PL (1) PL3317300T3 (lt)
PT (1) PT3317300T (lt)
RS (1) RS61444B1 (lt)
SI (1) SI3317300T1 (lt)
WO (1) WO2017001681A1 (lt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107417792B (zh) * 2017-08-29 2020-07-03 天津医科大学总医院 抗cd40-her2双特异性单链抗体及其在制备抗肿瘤药物中的应用
WO2019098563A1 (ko) 2017-11-20 2019-05-23 주식회사 엘지화학 회전식 디스크 시스템을 활용한 중금속 정성 및 정량 분석 디바이스 및 분석 방법
AU2019266042A1 (en) 2018-05-10 2021-01-14 Mirabiologics Inc. Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides
CN114573705B (zh) * 2022-03-17 2024-05-14 杭州师范大学 特异性启动抗乙型肝炎病毒t细胞免疫的双特异性抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
NZ521540A (en) * 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
JP3803790B2 (ja) * 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
EP3239178A1 (en) * 2007-12-14 2017-11-01 Bristol-Myers Squibb Company Binding molecules to the human ox40 receptor
EP2684896A1 (en) * 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
TWI707872B (zh) * 2014-05-29 2020-10-21 美商宏觀基因股份有限公司 特異性結合多種癌症抗原的三特異性結合分子和其使用方法
JP6602875B2 (ja) * 2015-01-26 2019-11-06 マクロジェニクス，インコーポレーテッド Ｄｒ５結合ドメインを含む多価分子

Also Published As

Publication number Publication date
PL3317300T3 (pl) 2021-05-31
KR20180053639A (ko) 2018-05-23
CA2990517C (en) 2023-08-29
WO2017001681A8 (en) 2018-03-29
CA2990517A1 (en) 2017-01-05
HRP20210152T1 (hr) 2021-03-19
SI3317300T1 (sl) 2021-04-30
CN108602886A (zh) 2018-09-28
AU2016285118A9 (en) 2019-08-01
US10813995B2 (en) 2020-10-27
HUE053128T2 (hu) 2021-06-28
DK3317300T3 (da) 2021-02-01
ES2848391T3 (es) 2021-08-09
AU2016285118A1 (en) 2018-02-22
AU2016285118B2 (en) 2021-12-16
US20180250396A1 (en) 2018-09-06
JP2018525347A (ja) 2018-09-06
WO2017001681A1 (en) 2017-01-05
EP3112381A1 (en) 2017-01-04
PT3317300T (pt) 2021-02-04
JP6876006B2 (ja) 2021-05-26
CN108602886B (zh) 2021-10-15
EP3317300A1 (en) 2018-05-09
CY1123839T1 (el) 2022-05-27
RS61444B1 (sr) 2021-03-31
EP3317300B1 (en) 2020-11-18

Similar Documents

Publication Publication Date Title
HK1244293A1 (zh) 用cd3xcd20雙特異性抗體治療腫瘤的方法
HK1232127A1 (zh) 雙特異性 抗體
HK1249114A1 (zh) 針對bcma的單克隆抗體
ZA201803874B (en) Humanized anti-cd73 antibodies
HK1246324A1 (zh) 抗pd-l1抗體
PL3519437T3 (pl) Przeciwciała dwuswoiste przeciwko p95HER2
HK1257760A1 (zh) 多特異性抗體
IL250415A0 (en) Antibodies against pd-l1
IL247273A0 (en) Multispecific antibodies
HK1258375A1 (zh) 人源化抗-cll-1抗體
PL3130606T3 (pl) Przeciwciała dwuswoiste aktywujące układ odpornościowy
IL247277A0 (en) Monoclonal antibodies against Ebola
GB201414823D0 (en) Multispecific antibodies
IL256579A (en) Human antibodies
EP3143154A4 (en) Chemically-locked bispecific antibodies
TWI560201B (en) Bi-specific antibodies for treating cancer
PL3371216T3 (pl) Humanizowane przeciwciała anty-BAG3
RS61444B1 (sr) Bispecifična antitela za upotrebu u imunoterapiji kancera
GB201506112D0 (en) Nanoparticle-based antigen specific immunotherapy
GB201511196D0 (en) Monoclonal antibodies